AstraZeneca Ireland Limited (20250002908). COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT COMPONENT 3 EXPRESSION
COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT COMPONENT 3 EXPRESSION
Organization Name
Inventor(s)
Melissa Lasaro of Sandy Hook CT US
Susan Faas Mcknight of Old Lyme CT US
Henryk T. Dudek of Belmont MA US
Bob Dale Brown of Littleton MA US
SungKwon Kim of Cheshire CT US
COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT COMPONENT 3 EXPRESSION
This abstract first appeared for US patent application 20250002908 titled 'COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT COMPONENT 3 EXPRESSION
Original Abstract Submitted
described herein are oligonucleotides (e.g., rnai oligonucleotides) containing a sense and antisense strands for targeting complement component 3 (c3) mrna. the rnai oligonucleotide may be used to inhibit c3 expression, levels, and/or activity in a cell. also, described herein are methods for using an oligonucleotide (e.g., an rnai oligonucleotide) for the prophylaxis or treatment of a disease, disorder, or condition mediated by complement pathway activation or dysregulation.
- AstraZeneca Ireland Limited
- Melissa Lasaro of Sandy Hook CT US
- Susan Faas Mcknight of Old Lyme CT US
- Henryk T. Dudek of Belmont MA US
- Jihye Park of Cambridge MA US
- Bob Dale Brown of Littleton MA US
- Chengjung Lai of Hudson NH US
- SungKwon Kim of Cheshire CT US
- C12N15/113
- A61P13/12
- A61P19/02
- A61P25/28
- A61P37/06
- CPC C12N15/113
